Bayer AG (OTCMKTS:BAYRY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Monday. The firm currently has a $111.00 price target on the stock. Zacks Investment Research’s price objective would suggest a potential upside of 11.52% from the company’s current price.

According to Zacks, “Bayer’s Life Science businesses continue to perform well, particularly the Pharmaceuticals and Consumer Health businesses. Newly launched products in the Pharmaceuticals segment should continue to perform impressively in the upcoming quarters. Bayer has made several acquisitions and entered into a number of deals to boost its portfolio in the past few quarters. In its attempt to create a global leader in agriculture, Bayer signed an agreement to acquire Monsanto for an aggregate value of $66 billion. We are further pleased with Bayer’s strategy of transforming itself into a pure life science company, which resulted in the sale of its Diabetes Care business and the spin-off of MaterialScience.  Estimates have been going up ahead of the company’s Q3 earnings release. However, we are concerned about the company’s dependence on the Pharmaceuticals segment for growth.”

BAYRY has been the subject of a number of other research reports. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Bayer AG in a report on Thursday, September 15th. Citigroup Inc. raised Bayer AG from a “neutral” rating to a “buy” rating in a report on Thursday, August 25th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Bayer AG in a report on Wednesday, September 14th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $120.50.

Analyst Recommendations for Bayer AG (OTCMKTS:BAYRY)

Bayer AG Company Profile

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic procedures.

Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.